In this review, we will discuss how specific classes of mutations have driven the need for newer treatments for GIST and compare historical and next-generation KIT/PDGFRA kinase inhibitors with a focus on their MOA. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.